
OpenAI to Give Away Some of the Technology That Powers ChatGPT
Since OpenAI unveiled ChatGPT three years ago, sparking the A.I. boom, it has mostly kept its technology under wraps. But many other companies, looking to undercut OpenAI, have aggressively shared their technology through a process called open source.
Now, OpenAI hopes to level the playing field and ensure that businesses and other software developers stick with its technology.
OpenAI's shift adds more fuel to a long-running debate between researchers who believe it is in every company's interest to open-source their technology, and national security hawks and A.I. safety pessimists who believe American companies should not be sharing their technology.
The China hawks and A.I. worriers appear to be losing ground. In a notable reversal, the Trump administration recently allowed Nvidia, the world's leading maker of the computer chips used to create A.I. systems, to sell a version of its chips in China.
Many of the San Francisco company's biggest rivals, particularly Meta and the Chinese start-up DeepSeek, have already embraced open source, setting OpenAI up as one of the few A.I. companies not sharing what it was working on.
The models being offered by OpenAI, called gpt-oss-120b and gpt-oss-20b, do not match the performance of OpenAI's most powerful A.I. technologies. But they still rank among the world's leading models, according to benchmark test results shared by the company. If people use those newly open-source models, OpenAI hopes they will also pay for its more powerful products.
'If we are providing a model, people are using us,' Greg Brockman, OpenAI's president and one of its founders, said in an interview with The New York Times. 'They are dependent on us providing the next breakthrough. They are providing us with feedback and data and what it takes for us to improve that model. It helps us make further progress.'
Open source has been a common practice among software companies for decades. As OpenAI and other companies began developing the kind of technology that would eventually drive chatbots like ChatGPT nearly a decade ago, they often open-sourced them.
'If you lead in open source, it means you will soon lead in A.I.,' said Clément Delangue, chief executive of Hugging Face, a company that hosts many of the world's open-source A.I. projects. 'It accelerates progress.'
But after OpenAI shared a technology called GPT-2 in late 2019, it stopped open-sourcing its most powerful systems, citing safety concerns. Many of OpenAI's rivals followed its lead. When OpenAI unveiled ChatGPT in late 2022, a growing chorus of A.I. experts argued that open-source technologies could cause serious harm.
This kind of technology can help spread disinformation, hate speech and other toxic language. Many researchers also worry that they could one day help people build bioweapons or wreak havoc as governments and businesses connected them to power grids, stock markets and weapons.
But the public conversation started to shift in 2023, when Meta shared an A.I. system called LLama. Meta's decision to go against the grain fueled a growing open-source ecosystem in the United States and other parts of the world. By late 2024, when DeepSeek released of a technology called V3, China had shown that its open-source systems could challenge many of the leading U.S. systems.
(The New York Times has sued OpenAI and its partner, Microsoft, accusing them of copyright infringement of news content related to A.I. systems. OpenAI and Microsoft have denied those claims.)
OpenAI said that it has released open-source systems in part because some businesses and individuals prefer to run these kinds of technologies on their own computer hardware, rather than over the internet. One of the new systems, gpt-oss-20b, is designed to run a laptop. The other, gpt-oss-120b, requires a more powerful system equipped with the specialized computer chips used to build the leading A.I. systems.
Mr. Brockman acknowledged that. A.I. can be used to both harm and empower people. But he said that the same is true of any powerful technology. He said that OpenAI has spent months — even years — building and testing its new open-source systems in an effort to reduce any harm.
The debate over open source is expected to continue as companies and regulators weigh the potential harm against the power of the time-tested tech method. Many companies have changed strategy over the years, and will continue to do so.
After creating a new superintelligence lab, Mark Zuckerberg and his fellow executives at Meta are considering their own shift in strategy.
They might abandon the A.I. technology that the company has freely shared with researchers and businesses, called Behemoth, and move toward a more guarded strategy involving closed source software.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Huawei's joint EV brand with Chery pledges $1.4 billion new investment
BEIJING (Reuters) -Huawei's joint electric vehicle brand with Chery said on Thursday that it will invest more than 10 billion yuan ($1.39 billion) and expand its research and development team to 5,000 people. It did not give a timeline for the move, which it said aims to strengthen the brand's lead in technology terms, according to a WeChat post. A new company was also created to integrate production, sales and services. ($1 = 7.1774 Chinese yuan renminbi)
Yahoo
24 minutes ago
- Yahoo
Exact Sciences to acquire US rights for Freenome's blood-based CRC test
Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based colorectal cancer (CRC) screening test in the US. Exact Sciences plans to accelerate the market adoption of the CRC blood test by leveraging its commercial infrastructure. Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November. Freenome is set to receive up to an additional $700m, contingent upon reaching specific milestones related to its CRC screening tests. These milestones include a $100m payment upon receiving first-line approval from the Food and Drug Administration (FDA) for their inaugural test and another $100m for the approval of a subsequent, next-generation test that meets or exceeds certain performance criteria, such as a minimum of 19% advanced precancerous lesions (APL) sensitivity and 83% overall CRC sensitivity. However, should the performance fall below these benchmarks, the payment would be adjusted accordingly. Furthermore, Freenome could earn $500m if its test is classified as a first-line A or B test in the US Preventive Services Taskforce (USPSTF) guidelines or if it achieves certain payer-contracted coverage requirements. Again, a decreased payment is applicable if the test is included in the USPSTF guidelines as a second-line A or B test. Freenome could be entitled to obtain royalties that vary between 0% and 10%, depending on the profitability of the test, while also adhering to standard provisions for royalty stacking. However, if specific conditions are not fulfilled, Exact Sciences reserves the right to end the agreement. Exact Sciences noted that it is committed to investing $20m annually over three years in joint research and development to further utilise the technology. Freenome retains rights to its CRC blood test when combined with other cancer screening tests. The license agreement also includes a senior convertible note purchase by Exact Sciences, amounting to $50m, with a coupon rate of 5% due in 2030. Freenome's PREEMPT CRC Study, which involved nearly 49,000 adults at average risk, demonstrated the CRC test's ability to identify 81.1% of CRC, including 63.5% at stage one, and 13.7% of APL, with a specificity of 90.4%. Freenome is also working on an 'improved version' of the test, which has shown enhanced performance in detection rates, and plans to submit a supplemental premarket approval application to the FDA once final clinical validation data are available. In a recent development, Exact Sciences expanded its collaboration with private insurer Humana to make the Cologuard Plus test available to eligible Humana Medicare Advantage members as an in-network service across the US. "Exact Sciences to acquire US rights for Freenome's blood-based CRC test" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
SMIC second-quarter profit declined 19.5% year-on-year
By Che Pan and Brenda Goh BEIJING (Reuters) -Semiconductor Manufacturing International Corp ,China's largest contract chip maker, reported on Thursday a 19.5% year-on-year decline in second-quarter profit. Profit attributable to owners of SMIC reached $132.5 million in the June quarter, missing analysts' estimates of $183.35 million, according to LSEG data. Revenue rose 16.2% to $2.2 billion, in line with market expectations of $2.2 billion, according to LSEG. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data